Post-IPO Equity - Advaxis
Investment Firm
Overview
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Announced Date
Aug 26, 2015
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
2
| Investor Name |
|---|
 Knight Therapeutics |
 Sectoral Asset Management |
Round Details and Background
Advaxis raised $25000000 on 2015-08-26 in Post-IPO Equity
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Company Funding History
13
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Oct 23, 2013 |  Post-IPO Equity - Advaxis | - | 26.5M | |
| May 27, 2011 | Post-IPO Debt - Advaxis | - | 6.0M | |
| Feb 24, 2012 | Post-IPO Debt - Advaxis | - | 1.0M | |
| May 29, 2012 | Post-IPO Equity - Advaxis | - | 4.5M |
Recent Activity
There is no recent news or activity for this profile.